Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS

Blood

Volumn 118, Issue 25, 2011, Pages 6529-6534

  Ng, Alvin C ^a   Khosla, Sundeep ^a   Charatcharoenwitthaya, Natthinee ^a   Kumar, Shaji K ^a   Achenbach, Sara J ^a   Holets, Margaret F ^a   McCready, Louise K ^a   Melton III, L Joseph ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Drake, Matthew T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; WNT PROTEIN;

AGED; AREAL BONE MINERAL DENSITY; ARTICLE; BONE DENSITY; BONE STRUCTURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR NECK; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRABECULAR BONE; VOLUMETRIC BONE MIERAL DENSITY;

EID: 84055177646     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351437     Document Type: Article

References (37)

1. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-493. (Pubitemid 40293498)
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
3. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
4. Melton LJ 3rd, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19(1):25-30. (Pubitemid 41295134)
5. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37(8):731-737.
6. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119(7):1728-1731. (Pubitemid 44258784)
7. Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood. 1997;90(9):3743-3750. (Pubitemid 27473447)
8. Diamond T, Levy S, Smith A, Day P, Manoharan A. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J. 2001;31(5):272-278. (Pubitemid 32734930)
9. Laroche M, Attal M, Dromer C, The Midi-Pyrenees Myeloma Group. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol. 1996;15(4):347-352. (Pubitemid 26239950)
10. Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(5):485-490. (Pubitemid 44141714)
11. Gregersen H, Jensen P, Gislum M, Jorgensen B, Sorensen HT, Norgaard M. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;135(1):62-67. (Pubitemid 44337663)
12. Golombick T, Diamond T. Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. Acta Haematol. 2008;120(2):87-90.
13. van Lenthe GH, Mueller TL, Wirth AJ, Muller R. Quantification of bone structural parameters and mechanical competence at the distal radius. J Orthop Trauma. 2008;22(8 Suppl):S66-72.
14. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123(1):106-109. (Pubitemid 37222765)
15. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
16. Riggs BL, Melton LJ 3rd, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004;19(12):1945-1954. (Pubitemid 41103408)
17. Laib A, Hildebrand T, Hauselmann HJ, Ruegsegger P. Ridge number density: a new parameter for in vivo bone structure analysis. Bone. 1997;21(6):541-546. (Pubitemid 28029698)
18. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care. 1998;6(5-6):329-337. (Pubitemid 29090456)
19. Parfitt A. Stereologic basis of bone histomorphometry: theory of quantitative microscopy and reconstruction of the third dimension. In: Recker R, ed. Bone Histomorphometry: Techniques and Interpretation. Boca Raton, FL: CRC Press; 1983:53-87.
20. Laib A, Newitt DC, Lu Y, Majumdar S. New model-independent measures of trabecular bone structure applied to in vivo high-resolution MR images. Osteoporos Int. 2002;13(2):130-136. (Pubitemid 34241033)
21. Laib A, Ruegsegger P. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone. 1999;24(1):35-39. (Pubitemid 28546704)
22. MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys. 2007;29(10):1096-1105. (Pubitemid 350052626)
23. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116(15):2651-2655.
24. Turner CH. Bone strength: current concepts. Ann N Y Acad Sci. 2006;1068:429-446. (Pubitemid 43824172)
25. Khosla S, Melton LJ 3rd. Clinical practice. Osteopenia. N Engl J Med. 2007;356(22):2293-2300.
26. Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010;24(10):1700-1712.
27. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2004;126(5):686-689. (Pubitemid 39221304)
28. Corso A, Arcaini L, Mangiacavalli S, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica. 2001;86(4):394-398. (Pubitemid 32428499)
29. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood. 1996;87(11):4762-4769. (Pubitemid 26162377)
30. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90(11):6323-6331. (Pubitemid 41606564)
31. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-2494. (Pubitemid 38010074)
32. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19-39. (Pubitemid 39335880)
33. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80(6):490-494. (Pubitemid 351677464)
34. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1093-1113, ix. (Pubitemid 350051347)
35. Pepe J, Petrucci MT, Mascia ML, et al. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int. 2008;82(6):418-426.
36. Berenson JR, Yellin O, Boccia RV, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res. 2008;14(19):6289-6295.
37. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464-2472. (Pubitemid 46999218)